Key result
Aspirin plus low-dose rivaroxaban linked to ~49% lower thrombin peak versus aspirin alone in PAD.
Why the study?
Patients with PAD benefit clinically from ASA plus low-dose rivaroxaban after EVR, but the differential effects on platelet activation status and reactivity remained to be characterized longitudinally.
Does dual therapy with aspirin and low-dose rivaroxaban inhibit platelet reactivity compared to aspirin monotherapy or aspirin plus clopidogrel in patients with peripheral arterial disease?
Observational (n=20)
Open-label
No
Does dual therapy with aspirin and low-dose rivaroxaban inhibit platelet reactivity compared to aspirin monotherapy or aspirin plus clopidogrel in patients with peripheral arterial disease?
Absolute Event Rate: 47.49% vs 95.92%
p-value: p=<0.05
In patients with peripheral arterial disease, dual therapy with aspirin and low-dose rivaroxaban significantly decreases thrombin generation and PAR-1 mediated platelet activation compared to aspirin monotherapy, providing mechanistic insight into its clinical benefits.
No takes yet. Share an insight, caveat, or question.
Provides mechanistic support for dual therapy in PAD; leaves open translation to clinical outcomes in prospective trials.
Jurk et al. (2022) conducted an observational in Peripheral Arterial Disease (PAD) (n=20). Acetylsalicylic acid plus rivaroxaban vs. Acetylsalicylic acid monotherapy was evaluated on Tissue factor-triggered thrombin peak in platelet-rich plasma (p=<0.05). Dual therapy with aspirin and low-dose rivaroxaban significantly reduced the tissue factor-triggered thrombin peak in platelet-rich plasma by 49% compared to aspirin monotherapy in patients with peripheral arterial disease.